Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.
androgen receptor antagonists
docetaxel
prostate cancer
Journal
Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
17
05
2020
accepted:
24
07
2020
pubmed:
25
9
2020
medline:
4
2
2021
entrez:
24
9
2020
Statut:
ppublish
Résumé
Optimal treatment for newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved, with many patients deriving benefit from the addition of docetaxel to androgen deprivation therapy (D-ADT). This study sought to define the therapy used and associated activity following D-ADT. Retrospective analysis of patients with mHSPC treated with one or more cycles of D-ADT who were identified from a prospectively maintained multisite prostate cancer database of patients treated in a community or academic center setting in Australia. The primary endpoint of this study was first-line time to treatment failure (1L TTF) for subsequent treatment of metastatic Castrate Resistant Prostate Cancer (mCRPC), with secondary endpoints of prostate-specific antigen (PSA) reduction >50% and time from 1L to second-line (2L) treatment initiation. A total of 93 patients received D-ADT for mHSPC, 85 (91%) had subsequent treatment for mCRPC. Median time to mCRPC (biochemical, clinical or radiographic) had been 14.8 months (95% confidence interval [CI], 11.9-16.5). 1L treatment was enzalutamide 47 patients (55%), abiraterone 23 (27%), cabazitaxel 7 (8%), docetaxel 4 (5%) and other therapies 4 (5%). Median 1L TTF was 6.3 months (95% CI, 4.9-7.6), PSA > 50% reduction was achieved in 32 of 89 patients (36%), median time from 1L to second-line treatment was 7.3 months (1.3-27.4), which did not differ significantly between treatment groups. Abiraterone, enzalutamide, cabazitaxel and docetaxel all demonstrate activity following progression on D-ADT. No difference in efficacy was detected between treatment options for mCRPC. Prospective trials investigating the optimal treatment sequence for prostate cancer following progression on D-ADT needed.
Substances chimiques
Androgen Antagonists
0
Docetaxel
15H5577CQD
KLK3 protein, human
EC 3.4.21.-
Kallikreins
EC 3.4.21.-
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36-42Informations de copyright
© 2020 John Wiley & Sons Australia, Ltd.
Références
Huggins C, Stevens RE, Jr, Hodges CV. Studies on prostatic cancer. I. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43(2):209-223.
Tannock IF, de Wit R, Berry WR, et al. docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.
Petrylak DP, Tangen CM, Hussain MHA, et al. docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-1520.
Kyriakopoulos CE, Chen Y-H, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomised phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080-1087.
Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30(12):1992-2003.
Gravis G, Boher J-M, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial. J Clin Oncol. 2015;33(7_suppl):140-140.
Sathianathen NJ, Philippou YA, Kuntz GM, et al. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer: A Cochrane Review. BJU Int. 2019;124(3):370-372.
Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152-160.
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: Extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71(2):151-154.
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197.
de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet. 2010;376(9747):1147-1154.
Oudard S, Fizazi K, Sengeløv L, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomised phase III Trial-FIRSTANA. J Clin Oncol. 2017;35(28):3189-3197.
Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402-1418.
Di Lorenzo G, Buonerba C, Faiella A, et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 2011;107(2):234-239.
Lavaud P, Gravis G, Foulon S, et al. Anticancer Activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-naïve prostate cancer in the GETUG-AFU 15 phase 3 trial. Eur Urol;73(5):696-703.
Francini E, Yip S, Ahmed S, et al. Clinical Outcomes of First-line abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer after androgen deprivation therapy + docetaxel or ADT alone for metastatic hormone-sensitive prostate cancer. Clin Genitourin Cancer. 2018;16(2):130-134.
Barata P, Emamekhoo H, Mendiratta P, et al. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. Prostate. 2018;78(13):1035-1041.
Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77(4):508-547.
Chin SN, Wang L, Moore M, Sridhar SS, et al. A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital. Curr Oncol. 2010;17(2):24-29.
Collette L. Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. Eur Urol. 2008;53(1):6-9.
Beekman KW, Fleming MT, Scher HI, et al. Second-line chemotherapy for prostate cancer: Patient characteristics and survival. Clin Prostate Cancer. 2005;4(2):86-90.
Gillessen S, Schmid S, Beltran H, et al. Platinum-based therapy in men with metastatic castration resistant prostate (mCRPC) with or without DNA repair defects: A multicentre retrospective analysis. Ann Oncol. 2018;29(suppl_8):viii271-viii302.
Anis H, Wang XV, Chen Y-H, et al. Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED. J Clin Oncol. 2020;38(6_suppl):162-162.